Evidence map›Paper›PMID 40862469›Full record

ArticleMolecular oncology2025

Expression and DNA methylation of 20S proteasome subunits as prognostic and resistance markers in cancer.

Ruba Al-Abdulla, Simone Venz, Ruslan Al-Ali, Martin Wendlandt, Mandy Radefeldt, Elke Krüger

Abstract read
In one paragraph

Article in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ruba Al-AbdullaInstitute of Medical Biochemistry and Molecular Biology, University Medicine of Greifswald, Germany.ORCID 0000-0002-5194-9801
Simone VenzInstitute of Medical Biochemistry and Molecular Biology, University Medicine of Greifswald, Germany.ORCID 0009-0004-6544-8524
Ruslan Al-AliCentogene, Rostock, Germany.
Martin WendlandtInstitute of Medical Biochemistry and Molecular Biology, University Medicine of Greifswald, Germany.ORCID 0009-0007-7151-3961
Mandy RadefeldtCentogene, Rostock, Germany.
Elke KrügerInstitute of Medical Biochemistry and Molecular Biology, University Medicine of Greifswald, Germany.ORCID 0000-0002-2551-242X

Funding

Universität Greifswald FOVB-2024-11
6 · The paper itself

Abstract

Proteasomes are involved in the maintenance of cellular protein homeostasis and the control of numerous cellular pathways. Single proteasome genes or subunits have been identified as important players in cancer development and progression without considering the proteasome as a multisubunit protease. We here conducted a comprehensive pan-cancer analysis encompassing transcriptional, epigenetic, mutational landscapes, pathway enrichments, and survival outcomes linked to the 20S proteasome core complex. The impact of proteasome gene expression on patient survival exhibited a cancer type-dependent pattern. Increased proteasome expression correlated with elevated activation of oncogenic pathways, such as DNA repair, MYC-controlled gene networks, MTORC1 signalling, oxidative phosphorylation, as well as metabolic pathways including glycolysis and fatty acid metabolism. Accordingly, potential loss of function variants of proteasome subunit genes are associated with improved patient survival. The TCGA-derived outcomes were further supported by gene expression analysis of THP-1 cells. Our study highlighted the importance of studying the proteasome as an enzymatic functional unit rather than separated subunits.

Indexed as

Biomarkers, TumorDNA MethylationDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticNeoplasmsProteasome Endopeptidase ComplexCell Line, TumorHumansPrognosisProtein SubunitsBiomarkers, TumorProteasome Endopeptidase ComplexProtein SubunitscancerDNA methylationpatient survivalproteasomeTCGA data

Identifiers

PMID40862469
PMCPMC12688171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.